UPDATE 1-Oxford COVID-19 vaccine tech maker Vaccitech targets $613 mln valuation in U.S. IPO

Biotech startup Vaccitech, which co-invented the COVID-19 vaccine developed by AstraZeneca Plc and Oxford University, said on Monday it was aiming for a valuation of up to $613 million in its U.S. initial public offering.